U.S. Bankruptcy Judge Craig Whitley in Charlotte, North Carolina ordered that tens of thousands of lawsuits against Johnson & Johnson be moved to New Jersey, according to a November 10, 2021 report from Reuters. Judge Whitley explained that his decision hinged on two factors: the fact that Johnson & Johnson is headquartered in New Jersey and the fact that a substantial amount of the country’s talc litigation is happening there.
The company further informs that it has produced around 750,000 replacement devices and repair kits. More than 250,000 are actually in consumers’ hands.
The delay in receiving new devices has been a point of frustration for users.
A late October hearing signaled movement toward trial for plaintiffs demanding compensation from the makers of paraquat weed killer, reports US Right to Know. U.S. District Judge Nancy Rosenstengel of the Southern District of Illinois prompted attorneys in more than 380 cases to begin assessing plaintiffs.
On October 22, 2021, Walmart announced it is recalling around 3,900 bottles of Better Homes and Gardens’ Essential Oil Infused Aromatherapy Room Spray with Gemstones, according to a report from the United States Consumer Product Safety Commission. The retail giant is recalling the room sprays due to the risk of serious injury and death.
Plaintiffs in talc cancer lawsuits against Johnson & Johnson have had a white-knuckle time of it after hearing the company’s plans to file bankruptcy. If you are among the worriers, you should know that your legal action remains alive and well. However, J&J’s maneuverings could change some aspects of how your case is handled.
According to the U.S. Food and Drug Administration (FDA), by January of 2020, the government agency had received 733 medical device reports (MDRs) of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) diagnoses and treatments.
Superior Court Judge Evelio Grillo for the County of Alameda, who oversees the California Ranitidine Product Cases Judicial Council Coordinated Proceedings (JCCP), has set a trial date of October 10, 2022, for the first cancer case trial. Drug makers Sanofi, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and Chattem will move forward as defendants. Although the JCCP functions similarly to a federal multidistrict litigation (MDL), these cases are adjudicated within the California state court system.
As of September 28, 2021, a total of 93 class actions had been filed against Continuous Positive Air Pressure (CPAP) maker Philips Respironics. The Judicial Panel on Multidistrict Litigation announced it will hear motions to consolidate or coordinate pretrial proceedings for these lawsuits.
The Levin Papantonio Rafferty law firm currently represents customers in claims to recover their investment losses in CION Investment Corp. On Tuesday, October 5, the shares of CION Investment Corp. began trading on the New York Stock Exchange under the ticker “CION.” Unfortunately for investors, shares closed trading on October 5 at $11.85 – representing a loss of over 40% of the principal for investors who purchased shares of CION at $10/share (shares underwent a reverse share split in September, resulting in an approximate halving of investors shares).
The U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication (DSC) regarding the arthritis and ulcerative colitis drug Xeljanz (and Xeljanz XR), otherwise known as tofacitinib. After studying the results of a large, randomized safety clinical trial of the medicine, the agency stated there was evidence of “serious heart-related events,” including heart attack, stroke, cancer, blood clots, and death.
The Levin Papantonio Rafferty law firm announced today that it has filed claims on behalf of retiree investors who are former clients of Sarasota-area Financial Advisor Marc Korsch and NAV Advisors. According to his FINRA Brokercheck report, Mr. Korsch’s securities registration terminated last week on Friday, September 3 – which may leave clients stuck with illiquid investments that they cannot sell.
Investors in Moody National REIT II may have suffered devastating losses. Moody announced that its Board had decided to postpone the valuation of Moody National REIT II shares on August 5, 2021. In the past Moody declared its updated NAV at the end of the calendar year, but Moody has yet to update its NAV since December 2019.
The U.S. Food and Drug Administration (FDA) issued notice that Philips Respironics recalled its V60 Plus Ventilators Equipped with High Flow Therapy (software version 3.00 and 3.10) and all V60 ventilators that have been upgraded to enable High Flow Therapy with this software. The manufacturer distributed the affected devices between May 1, 2009, and June 2, 2021.
UC San Diego Health announced on July 27, 2021, that the health care provider experienced unauthorized access to employee email accounts. According to a press release issued on this date, patients’ continuity of care did not suffer as a result of the security event.
Parking REIT investors may have suffered losses of over 75% of their investment principal, based on recent tender offers of less than $6.00 per share made by MacKenzie Capital Management. Furthermore, data from limited secondary trading data sources shows a sale in June 2020 for amounts as low as $5.01 per share. The Parking REIT’s board estimated the share value at $11.75 as recently as June 2021, but even if that share value estimated was correct investors who paid $25.00 per share may have lost over 50% of their investment principal.
Atlas Growth Partners LP was a high risk limited partnership dedicated to developing and producing natural gas, crude oil and NGLs. Based on Atlas Growth Partner’s SEC Filings, investors who were sold Atlas Growth Partners may have lost almost 99% of their investment principal. Atlas Growth Partners recently disclosed in a filing with the SEC that there were “significant risks and uncertainties related to our inability to satisfy our current liabilities raise substantial doubt about our ability to continue as a going concern.
Investors who purchased shares of Didi Global, the Chinese ride-sharing company, may have the right to file their own claim to recover their losses. While there are currently uncertified class actions that have been filed, securities class actions frequently result in notoriously small settlements as a percentage of the damages suffered by class members.
If your broker recommended you invest in complex, non-traditional, leveraged, or inverse ETFs, you may have a right to bring a claim to recover losses you may have suffered.
Phillips Respironics has issued a voluntary recall of around 4 million CPAP and BiLevel PAP devices. According to the manufacturer’s notification, the company’s quality management system revealed these products pose serious health risks and potentially life-threatening injuries for users.
The first-generation DreamStation product family comprises the Philips medical devices most affected by the recall.
If your broker recommended you invest in FS Investment Corporation II, you may have a legal claim to recover losses you have suffered.
800.277.1193
Phone